Diversity-oriented synthesis encoded by deoxyoligonucleotides
- PMID: 37582753
- PMCID: PMC10427684
- DOI: 10.1038/s41467-023-40575-5
Diversity-oriented synthesis encoded by deoxyoligonucleotides
Erratum in
-
Author Correction: Diversity-oriented synthesis encoded by deoxyoligonucleotides.Nat Commun. 2023 Nov 21;14(1):7589. doi: 10.1038/s41467-023-43518-2. Nat Commun. 2023. PMID: 37989745 Free PMC article. No abstract available.
Abstract
Diversity-oriented synthesis (DOS) is a powerful strategy to prepare molecules with underrepresented features in commercial screening collections, resulting in the elucidation of novel biological mechanisms. In parallel to the development of DOS, DNA-encoded libraries (DELs) have emerged as an effective, efficient screening strategy to identify protein binders. Despite recent advancements in this field, most DEL syntheses are limited by the presence of sensitive DNA-based constructs. Here, we describe the design, synthesis, and validation experiments performed for a 3.7 million-member DEL, generated using diverse skeleton architectures with varying exit vectors and derived from DOS, to achieve structural diversity beyond what is possible by varying appendages alone. We also show screening results for three diverse protein targets. We will make this DEL available to the academic scientific community to increase access to novel structural features and accelerate early-phase drug discovery.
© 2023. Springer Nature Limited.
Conflict of interest statement
C.J.G. is a shareholder in and employee of Kisbee Therapeutics. C.W.C. is an advisor to Anagenex. P.A.C. is an advisor to nference, Inc., Pfizer, Inc., and Belharra Therapeutics. B.M. is a scientific advisor to Magnet Biomedicine. S.L.S. is a shareholder and serves on the Board of Directors of Jnana Therapeutics and Kojin Therapeutics; is a shareholder and advises Kisbee Therapeutics, Belharra Therapeutics, Magnet Biomedicine, Exo Therapeutics, and Eikonizo Therapeutics; advises Vividian Therapeutics, Eisai Co., Ltd., Ono Pharma Foundation, F-Prime Capital Partners, and the Genomics Institute of the Novartis Research Foundation; and is a Novartis Faculty Scholar. All other authors declare no competing interests.
Figures
References
-
- Gerry CJ, Schreiber SL. Recent achievements and current trajectories of diversity-oriented synthesis. Curr. Opin. Chem. Biol. 2020;56:1–9. - PubMed
-
- Schreiber SL. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science. 2000;287:1964–1969. - PubMed
-
- Galloway, W. R. J. D., Isidro-Llobet, A. & Spring, D. R. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nat. Commun.1, 80 (2010). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
